Praziquantel : avaliação in vivo do efeito de nanopartículas no metabolismo de Cisticercos de Taenia Crassiceps

Abstract

The praziquantel (PZQ) is a drug commonly used to treat taeniasis and cysticercosis. Some studies have shown the effects of PZQ in the energy and respiratory metabolism of the parasite Taenia crassiceps, experimental model to T. solium. Due to its low solubility in water PZQ, then requiring high doses administered to achieve tissue larval parasite, some strategies are being studied and used to improve the solubility of PZQ. The nanoparticles occupy a prominent position among drug release systems currently available because they present colloidal stability, chemical resistance and production are easy. Thus, this study aimed to evaluate the effect of nanoparticle PZQ under the biochemical aspects of Taenia crassiceps. For the experiments we used 40 female mice BALB /c infected for 30 days with cysticerci of T. crassiceps. The mice were divided in eight groups, with five animals each, a negative control (not treated with PZQ), a positive control (treated with conventional PZQ), three groups treated with the polymers P-188, P-407 and PVA and three groups treated with the nanoformulations PZQ, NS4, NS5 and NS6. The results of this study revealed increased concentration of glucose and pyruvate in the groups treated with NS5, compared to negative and positive control. It was observed partial reversal of the TCA cycle, by the absence or reduction in the production of the organic acids citrate and α-ketoglutarate in groups treated with NS4 and NS5. The failure to detect acetate in the groups treated with PZQ, P-407 and in the groups treated with nanoformulations suggests the use of Acetyl-CoA to produce acetoacetate has been converted to β-hydroxybutyrate. Activation of the urea cycle suggested by the increase in the concentration of this substance in the groups treated with NS4 and polymers P-188 and P-407. It is concluded that nanoformulations altered metabolism of praziquantel cysticerci of T. crassiceps primarily in the groups treated with the NS4 and NS5 nanoformulations.